About Liberate Bio
Liberate Bio focuses on advancing non-viral delivery technologies for nucleic acid cargoes such as ASOs and siRNAs. The company aims to develop new vehicles to deliver oligonucleotide cargos, addressing genetic disorders. With a team of 50 employees, Liberate Bio operates within the biotechnology industry, working on innovative solutions for targeted delivery systems.
Open positions (3)
Company details
Funding
Total raised
$31M
Last stage
Seed
Investors
Founders
Nessan Bermingham
Serial biotech entrepreneur and Operating Partner at Khosla Ventures; co-founder and founding CEO of Intellia Therapeutics.
LinkedInMichael J. Mitchell
Assistant Professor of Bioengineering at the University of Pennsylvania; expert in lipid nanoparticle drug delivery.
Stephen Scully
Previously Principal Scientist at Intellia Therapeutics; expert in particle formulations for nucleic acid delivery.
Theresa M. Reineke
Professor at the University of Minnesota with expertise in polymer chemistry and nucleic acid delivery systems.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.